Bengaluru, Strand Life Sciences, a subsidiary of Reliance Industries Limited, today announced the launch of its advanced proteomics capabilities, powered by Olink™ Explore HT, marking a key milestone in expanding large-scale multi-omics research in India and South Asia. Every living cell produces thousands of proteins — the molecular machines that carry out virtually every biological function in the body, from fighting infection to regulating metabolism.  Proteomics is the large-scale study of these proteins: what they are, how many are present, and how their levels shift in health and disease. It tells us what is actually being built and in what quantities — making it one of the most direct windows into the biology of disease. Next-generation proteomics platforms have enabled the simultaneous analysis of thousands of proteins from a single, small blood sample. The result is a richer, faster, and far more actionable picture of disease biology — one that supports more precise treatment selection, and the discovery of new drug targets. As part of this milestone, Strand has successfully completed a proteomics project for a biopharma partner, involving patients with chronic kidney disease, demonstrating the platform's potential in translational research and clinical studies. Olink™ Explore HT enables the measurement of over 5,400 protein biomarkers from just 2 µL of sample — roughly one-twenty-fifth of a single drop of blood — allowing Strand to deliver integrated proteomics, genomics, and clinical insights for advanced research and drug discovery. For pharmaceutical and biotechnology companies, this capability represents a transformational change. Research programmes that once required time intensive sequential investigation can now be compressed into integrated, large-scale studies.  For clinicians and patients, the promise is equally significant. Biomarkers identified through proteomics can guide treatment decisions with greater confidence and open new frontiers in precision medicine.